(Click on image to enlarge)

(Click on image to enlarge)

Obesity is rising and in the last 35 years, has more than doubled. The world population from 1999 to today is 42% or 22 million adults with a body mass index of 40 or higher.  

Competition with Novo-Nordisk is a factor, but analysts expect 20% or higher annual growth from the company for the next few years.  

Earnings expectations for the company are $3.24 per share this year.  

Novo-Nordisk (NVO) is an honorable mention pick in my Outlook 2025. 

Now, from a technical standpoint, it looks not only way oversold (even on the monthly charts), but also now at major support levels. 

What do we see in the charts? 

On the weekly chart, NVO fell right down to the 200-week moving average. Clearly, the leadership is showing a gross lack of leadership. 

Real Motion has yet to indicate a mean reversion, which is very interesting as the last one was in October 2022, right before the huge runup.  

The Daily chart… 

is less interesting than the weekly chart. Once again, zooming out is helpful, just as it has been in the Economic Modern Family. 

Most notable on the Daily chart is that today we broke down under the low from December 20th and closed just shy of it. 

That makes prior low pivotal. 

As far as a trade, we will use the classic reversal pattern to determine entry with risk parameters. 

My favorite investment is a solid company that falls to a major moving average, is oversold and then reverses on good volume. 

More By This Author:

Not A Turnaround But Could Be Soon Novo Nordisk
Why Is Stagflation On The Table?
TA: Nasdaq Joins Indices In Confirmed Caution Phase